Irbesartan/Hydrochlorothiazide Zydus (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone‑driven sodium retention. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, increasing urinary excretion of sodium and water. The dual action reduces both vascular tone and fluid volume, resulting in lower arterial pressure.

The appropriate dose is individualized by the prescribing clinician based on the patient’s blood‑pressure level, renal function, electrolyte status and response to therapy. No fixed regimen is provided here; the prescriber sets the dose according to clinical guidelines and patient needs.

Safety data in pregnancy are limited and the product is classified as having an unknown pregnancy category. It is generally avoided during pregnancy because of potential fetal risk. Breastfeeding mothers should consult a healthcare professional, as the drug may be excreted in milk.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with other ARB/thiazide combinations such as Losartan/HCTZ, Irbesartan offers a similar potency in AT₁ receptor blockade but may have a slightly different pharmacokinetic profile. Choice between products often depends on physician preference, patient tolerance, and specific formulary considerations.

Store the tablets at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect from excess moisture, heat and direct sunlight. Do not refrigerate or freeze the product.

The medication is taken orally, usually once daily, with or without food, and swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events include severe dehydration, acute kidney injury, hyperkalemia, allergic reactions such as angioedema, gout attacks and marked hypotension. Patients should seek immediate medical attention if they experience symptoms like swelling of the face or throat, rapid weight loss, or persistent dizziness.

The combination is contraindicated in patients with known hypersensitivity to irbesartan, hydrochlorothiazide or any component of the formulation, in those with severe renal impairment, anuria, or in individuals with a history of angioedema related to ARB therapy. Caution is also advised for patients with electrolyte disorders.